Related Experiment Video
Updated: Dec 29, 2025
10:30
A Generalized Method for Determining Free Soluble Phenolic Acid Composition and Antioxidant Capacity of Cereals and Legumes
Published on: June 10, 2022
7.9K
Antidiabetic components contained in vegetables and legumes.
Guang-Yan Tang1, Xue-Juan Li, Hong-Yu Zhang
1School of Life Sciences, Shandong University of Technology, Zibo 255049, P. R. China.
Molecules (Basel, Switzerland)
|June 19, 2008
Summary
Consuming vegetables and legumes may lower type 2 diabetes risk. Researchers identified potential antidiabetic compounds in these plants by searching traditional Chinese medicine databases.
Area of Science:
- Nutritional Science
- Pharmacology
- Epidemiology
Background:
- Epidemiological studies in China show a link between vegetable/legume intake and reduced type 2 diabetes (T2D) risk.
- The specific antidiabetic mechanisms of these plant-based foods are not fully understood.
- Traditional Chinese Medicine (TCM) databases offer a rich source of information on plant-derived compounds.
Purpose of the Study:
- To identify potential antidiabetic components from vegetables and legumes.
- To explore the utility of medicinal databases, particularly TCM resources, for discovering food-based therapeutic agents.
- To elucidate the health benefits of plant consumption in relation to T2D prevention.
Main Methods:
- Literature review and data mining of medicinal databases, focusing on TCM resources.
- Analysis of epidemiological data linking dietary patterns to T2D risk.
- Cross-referencing food components with known pharmacological activities relevant to diabetes.
Main Results:
- Identification of specific compounds in vegetables and legumes with potential antidiabetic properties.
- Demonstration of the feasibility of using medicinal databases to uncover functional food components.
- Corroboration of the inverse association between plant consumption and T2D risk.
Conclusions:
- Vegetables and legumes contain components that may contribute to type 2 diabetes prevention.
- Medicinal databases, especially TCM, are valuable tools for identifying bioactive food constituents.
- Further research into these identified components could lead to novel dietary strategies for T2D management.
Related Concept Videos
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
475
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
475
01:23Dipeptidyl Peptidase 4 Inhibitors
497
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
497
01:06Oral Hypoglycemic Agents: Glinides
514
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
514
01:24Glucagon-like Receptor Agonists
767
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
767
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
536
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
536
01:22Diabetes Mellitus: Overview and Type I Subtype
4.7K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
4.7K